Adenovirus Type 4 and Type 7 Vaccine, Live, Oral, Enteric Coated Tablets for Oral Administration
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DLA TROOP SUPPORT
Contract Value
Not provided
Codes & Classification
Solicitation Number
SPE2DP-25-R-0001
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
Documents2
The Defense Logistics Agency (DLA) Troop Support has issued a solicitation (SPE2DP-25-R-0001, including Amendment 0001) for the procurement of Adenovirus Type 4 and Type 7 Vaccine, Live, Oral, Enteric Coated Tablets intended for oral administration. This procurement seeks to secure a reliable supply of these specific vaccines, which are critical for the prevention of adenovirus infections, particularly in settings where such outbreaks can have significant health impacts, such as among military personnel.
The scope of this solicitation encompasses the manufacturing and delivery of live, oral, enteric-coated tablets containing Adenovirus Type 4 and Type 7. The vaccines must be produced in accordance with all applicable pharmaceutical manufacturing standards, ensuring safety, efficacy, and regulatory compliance. The intended outcome is to maintain readiness and protect the health of individuals at risk of adenovirus infection by ensuring timely and consistent access to these vaccines.
Key requirements for this procurement include the ability to manufacture pharmaceutical preparations under NAICS code 325412 (Pharmaceutical Preparation Manufacturing), with the product classified under Product Service Code 6505 (Drugs and Biologicals). Offerors must demonstrate the capacity to deliver live, oral, enteric-coated vaccine tablets that meet all specified quality and regulatory standards. The solicitation does not specify any set-aside restrictions, indicating that it is open to all qualified vendors regardless of business size or socioeconomic status.
The place of performance for this contract is within the United States. The DLA Troop Support, a federal office, serves as the contracting entity responsible for this procurement. Interested parties should direct all inquiries and correspondence to the primary contact, Yu Chen, who can be reached via email at [email protected] or by phone at 445-737-7606.
The solicitation was originally posted on September 23, 2025, and, following Amendment 0001, the closing date for responses has been extended to November 7, 2025, at 3:00 PM EST. All other terms and conditions outlined in the original solicitation remain unchanged. Contractors considering this opportunity should review the solicitation documents and attachments available on SAM.gov (Opportunity ID: 1445579ef6c5417a8bf86ded894ad4a3) to ensure alignment with their manufacturing capabilities and compliance with federal procurement requirements.
This procurement represents a significant opportunity for qualified pharmaceutical manufacturers to support the health and readiness of U.S. personnel by supplying a critical vaccine product. Contractors are encouraged to assess their ability to meet the technical, regulatory, and delivery requirements outlined in the solicitation before submitting a response.